ACE inhibitors were the first pharmacological class shown to benefit heart failure treatment in the general population—and they’ve also played a critical role in improving outcomes for Duchenne (DMD) and Becker (BMD) cardiomyopathy. Despite strong evidence from randomized trials and registry analyses supporting their use, these treatments remain underutilized in DMD patients, even those with significant cardiac dysfunction.
On April 17. 2025, the C-Path team hosted an in-depth webinar that discussed:
- The role of ACE inhibitors in slowing the progression of myocardial dysfunction in DMD and BMD
- Key research findings and expert guidelines
- How ACE inhibitors have paved the way for broader heart failure treatments, including MRAs, beta-blockers, sacubitril/valsartan, and SGLT2 inhibitors
This session will provide a comprehensive overview of the latest research and encourage discussion on these important topics. Watch the recording now:
